Gracell Biotechnologies  logo
Gracell Biotechnologies GRCL

Quarterly report 2022-Q2
added 08-15-2022

report update icon

Gracell Biotechnologies Financial Statements 2011-2026 | GRCL

Annual Financial Statements Gracell Biotechnologies

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.97 B 766 M - - - - - - - - -

Shares

329 M 37 M - - - - - - - - -

Historical Prices

6.04 - - - - - - - - - -

Net Income

-452 M -212 M -139 M -60.8 M - - - - - - -

Operating Income

-464 M -214 M -147 M -62.5 M - - - - - - -

Interest Expense

5.06 M 2.16 M -21 K 20 K - - - - - - -

EBITDA

-419 M -207 M -141 M -59.5 M - - - - - - -

Operating Expenses

- 214 M 147 M 62.5 M - - - - - - -

General and Administrative Expenses

137 M 45.6 M 27.4 M 10.3 M - - - - - - -

All numbers in CNY currency

Quarterly Income Statement Gracell Biotechnologies

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- - 338 M - 338 M - - - 99 M - - - 99 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in CNY currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Gracell Biotechnologies GRCL
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Gracell Biotechnologies plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Graybug Vision Graybug Vision
GRAY
- -11.23 % $ 9.65 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.16 -2.61 % $ 2.54 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.79 -6.17 % $ 4.31 M chinaChina
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.71 -2.88 % $ 1.11 B canadaCanada
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 164.05 -1.4 % $ 8.16 B usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.55 -2.06 % $ 1.39 B britainBritain
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 64.53 -1.48 % $ 12.4 B usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 58.53 -2.03 % $ 11.2 B usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
CohBar CohBar
CWBR
- -15.44 % $ 2.2 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
- -5.98 % $ 34.1 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 3.25 -1.52 % $ 3.8 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 25.84 -3.8 % $ 692 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Codexis Codexis
CDXS
$ 0.98 -3.92 % $ 71.9 M usaUSA
Certara Certara
CERT
$ 7.24 2.7 % $ 1.16 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
- - $ 105 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
- 7.55 % $ 38.1 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.65 - $ 155 M usaUSA
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA